Seres Therapeutics (MCRB) EBT (2014 - 2026)
Seres Therapeutics (MCRB) posted EBT of -$25.6 million for Q1 2026, down 35.03% sequentially from -$18.9 million in Q4 2025, and up 18.83% YoY from -$21.5 million in Q1 2025.
Seres Therapeutics (MCRB) EBT (2014 - 2026) Analysis & Trends
Seres Therapeutics has reported EBT for 13 years, with the latest figure at -$25.6 million in Q1 2026.
- Quarterly EBT rose 18.83% year-over-year to -$25.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$342.1 million (down 149.33% YoY) and the FY2025 annual result came in at -$402.7 million, up 6.58% from the prior year.
- EBT declined to -$25.6 million in Q1 2026 per MCRB's latest filing, from -$18.9 million in the prior quarter.
- Over five years, EBT peaked at $44.4 million in Q2 2023 and troughed at -$16.5 billion in Q3 2022.
- A 5-year average of -$1.1 billion and a median of -$46.4 million in 2023 frame the typical range for EBT.
- The sharpest annual moves came in 2022 and 2023: EBT plunged 379.31% in 2022, then jumped 104.84% in 2023.
- Over 5 years, EBT stood at -$60.3 million in 2022, then gained by 13.12% to -$52.4 million in 2023, then advanced by 25.92% to -$38.8 million in 2024, then jumped by 51.25% to -$18.9 million in 2025, then sank by 35.03% to -$25.6 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$25.6 million, -$18.9 million, and -$145.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | Seres Therapeutics | 43.82 Mn | 43.82 Mn | - | -21.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -98.45 Mn |
| Mar 31, 2026 | -25.56 Mn |
| Dec 31, 2025 | -18.93 Mn |
| Sep 30, 2025 | -145.16 Mn |
| Jun 30, 2025 | -152.47 Mn |
| Mar 31, 2025 | -31.50 Mn |
| Dec 31, 2024 | -38.84 Mn |
| Sep 30, 2024 | -33.88 Mn |
| Jun 30, 2024 | -33.00 Mn |
| Mar 31, 2024 | -36.39 Mn |
| Dec 31, 2023 | -52.42 Mn |
| Sep 30, 2023 | -46.41 Mn |
| Jun 30, 2023 | 44.42 Mn |
| Mar 31, 2023 | -73.97 Mn |
| Dec 31, 2022 | -60.34 Mn |
| Sep 30, 2022 | -16.47 Bn |
| Jun 30, 2022 | -917.06 Mn |
| Mar 31, 2022 | -57.48 Mn |
| Dec 31, 2021 | -49.69 Mn |
| Sep 30, 2021 | -19.81 Bn |